Only 14 genes (CYP2C8, CYP11B2, AGT, AGTR1, AGTR2, ACE, ADRB2, LEP, MTHFR, NOS3, HFE, CNNM3, IGF2BP2, and SCNN1B) were identified to have an interaction with FDA approved marketed HTN drugs (Figure 3 and Table S4). Here, CYP2C8 is linked to hypertensive disorder.